PMID- 18497545
OWN - NLM
STAT- MEDLINE
DCOM- 20080606
LR  - 20170124
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 29
IP  - 1
DP  - 2008
TI  - Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative 
      immunohistochemical and fluorescence in situ hybridization study.
PG  - 18-27
LID - 10.1159/000132567 [doi]
AB  - Overexpression and/or gene amplification of the HER2 oncogene predicts worse 
      prognosis and altered sensitivity to chemotherapy. Trastuzumab is capable of 
      improving prognosis of HER2-positive breast cancer, but for the success of 
      treatment appropriate HER2 testing is essential. Our aim was to determine the 
      value of immunohistochemical (IHC) screening prior to fluorescence in situ 
      hybridization (FISH). We assessed five conventional IHC assays (NCL-CB11, Pathway 
      CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, 
      combined with FISH on 199 invasive breast cancer cases. Taking FISH as the 
      endpoint, we calculated sensitivity, specificity, positive and negative 
      predictive values (PPV, NPV) and accuracy for all IHC assays with either taking 
      both 2+/3+ cases or only 3+ cases as IHC positives. With 2+/3+ cases HercepTest 
      showed 100% sensitivity and NPV, while the highest specificity, PPV and accuracy 
      was associated with RM-4B5 (97.36, 80 and 95.34%, respectively). The second 
      highest values belonged to either NCL-CB11 or Pathway CB11. When calculating only 
      with 3+ cases, the results were reversed with increased specificity, PPV and 
      accuracy. Our findings suggest that improving sensitivity by using two parallel 
      IHC reactions might be beneficial; we recommend primarily HercepTest and Pathway 
      CB11. Nevertheless, we may consider performing FISH analysis without prior IHC 
      screening.
CI  - (c) 2008 S. Karger AG, Basel
FAU - Egervari, Kristof
AU  - Egervari K
AD  - Department of Pathology, Medical and Health Science Center, University of 
      Debrecen, Debrecen, Hungary.
FAU - Szollosi, Zoltan
AU  - Szollosi Z
FAU - Nemes, Zoltan
AU  - Nemes Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080523
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Antibodies)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma, Mucinous/diagnosis/*immunology
MH  - Antibodies/*immunology
MH  - Breast Neoplasms/diagnosis/*immunology
MH  - Carcinoma, Ductal, Breast/diagnosis/*immunology
MH  - Carcinoma, Lobular/diagnosis/*immunology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*immunology
EDAT- 2008/05/24 09:00
MHDA- 2008/06/07 09:00
CRDT- 2008/05/24 09:00
PHST- 2007/09/06 00:00 [received]
PHST- 2008/01/14 00:00 [accepted]
PHST- 2008/05/24 09:00 [pubmed]
PHST- 2008/06/07 09:00 [medline]
PHST- 2008/05/24 09:00 [entrez]
AID - 000132567 [pii]
AID - 10.1159/000132567 [doi]
PST - ppublish
SO  - Tumour Biol. 2008;29(1):18-27. doi: 10.1159/000132567. Epub 2008 May 23.